The Mood Disorders Program Thomas Jefferson University is actively seeking participants for the following studies.
- Genetic testing clinical trial:
This is a clinical trial of how useful genetic testing is in guiding the treatment of major depression. Patients who are currently suffering from major depression will receive genetic testing and then be treated with an antidepressant. In half the cases, the treating psychiatrist will know the genetic testing result in advance. In other patients, the genetic testing result won't be available until after 8 weeks of treatment.
No patient will receive plaebo. The study will last for 9 weeks and will require 6 visits. Participants will be reimbursed for both their time and for travel expenses.
- Genetic testing Study
A genetic test will be done in persons in persons who are now taking OR have ever in the past taken certain antidepressant medications and who had EITHER:
a. Significant side effects on the antidepressant, OR
b. Less than a 30% reduction in depression.
Only two visits are required. There is no treatment in this study. Patients and their treating clinicians will be given the results of the genetic testing and Dr. Mago, the study psychiatrist, will discuss the genetic test results. Participants will be reimbursed for both their time and for travel expenses.
- Sexual dysfunction study:
This is a clinical trial for patients whose major depressive disorder has remitted with an antidepressant but who have antidepressive-related sexual dysfunction. That is, currently the person has no depression or minimal depression, but significant sexual dysfunction that is thought to be due to the antidepressant.
Patients will be treated with eihter vilazodone (Viibryd) or sertraline (Zoloft), both which are FDA-approved antidepressants. No patient will receive placebo. The study will last for up to 14 weeks and require 10 visits. Participants will be reimbursed for both their time and for travel expenses.
- Major depression in persons with coronary artery disease:
This clinical trial for the treatment of major depression in persons who also have had coronary artery disease (heart attack, blockage in heart arteries, coronary bypass surgery, etc.) in the past. Persons who are currently significantly depressed will be treated with vortioxetine (Brintellix), an FDA-approved antidepressant for 8 weeks. All patients will receive the medication; no placebo is used. Participants will be reimbursed for both their time and for travel expenses.
- Excessive Sweating Study
Patients with clinical depression who have complaints of excessive sweating thought to be a side effect of their antidepressant may be suitable for participation in an ongoing clinical trial in which participants will have another medication added to an antidepressant to assess how well this potential drug works to treat sweating caused by antidepressants. All patients will receive the medication; no placebo is used.
In the News
Matthew Wintersteen, Ph.D., Assistant Professor in the Department of Psychiatry and Human Behavior is the Principal Investigator of a $1.2 million subcontract for suicide prevention efforts from the Commonwealth of Pennsylvania received by Jefferson.
"Two of our faculty members will be among the awardees at the Philadelphia Psychiatric Society's Annual Benjamin Rush Awards Gala that will be held on Friday Friday, November 6, 2015 at the Merion Cricket Club in Haverford, PA. Fayez El-Gabalawi, MD will receive the Psychiatric Educator of the Year award, and Shivkumar Hatti, MD, will receive the Daniel Blain Award."